Mannooligosaccharides (MOS) were purified from the thermally hydrolyzed mannan in spent coffee grounds, with the aim of achieving the full utilization of natural unused food material. The effects of MOS on fecal microflora and the defecating conditions in eight healthy volunteers were investigated. The subjects were administered MOS at 1.0 g/day and 3.0 g/day for 2 weeks. A 2 week interval was observed between the two dose intake periods. The content of Bifidobacterium significantly increased during the two periods (pϽ Ͻ0.05). It appeared that MOS intake had a tendency to increase the content of Bifidobacterium in fecal microflora depending on the dosage level. Defecating conditions were also improved at both dosage levels (pϽ Ͻ0.05). These results suggested that MOS ingestion caused Bifidobacterium to be the predominant bacteria in the intestine and improved defecation.
Recently the increasing amount of coffee beverage consumption has led to an increase in the discharge of spent coffee grounds. Spent coffee grounds are disposed of as industrial waste, however, these grounds contain mannan. The authors obtained mannooligosaccharides (MOS) from mannan in spent coffee grounds by thermal hydrolysis. It is quite meaningful to fully utilize the by-products produced in the food industry. It is also important to evaluate the physiological functions of newly extracted oligosaccharides for effective application to food products.
In a previous in vitro study, fractionated MOS from hydrolyzed coffee mannan was used by Bifidobacterium adolescentis, Lactobacillus acidophilus and L. gasseri, but not used by harmful bacteria such as Clostridium perfringens and Escherichia coli (Asano et al., 2001) . Furthermore, MOS were resistant to digestive enzymes and were fermented by human fecal bacteria. The fermentation products were short chain fatty acids (SCFA) (Asano et al., 2003) . These results suggested that MOS were indigestible saccharides, which were selectively utilized by beneficial bacteria and converted to SCFA in the human large intestine. Short chain fatty acids are thought to lower the pH in the human intestine and to thereby prevent the growth of harmful bacteria like Cl. perfringens, and to cause greater constipation. However, it was not clear whether the administration of MOS influenced the intestinal microflora and defecation frequency.
In this paper, we investigated the effects of MOS on human fecal microflora in vivo and the defecation of eight healthy volunteers, using two different doses (1.0 g/day and 3.0 g/day).
Materials and Methods
Preparation of mannooligosaccharides (Asano et al., 2003) The thermally hydrolyzed product from spent coffee grounds was decolorized using active carbon powder (Umehachi; Taihei Chemicals, Osaka) and desalted using cation exchange resin (SKIB; Mitsubishi Chemicals) and anion exchange resin (WA30; Mitsubishi Chemicals, Tokyo). One hundred grams of a mixture of monosaccharides and MOS mixture were obtained from 300 g of the hydrolyzed products of spent coffee grounds. Monosaccharides were eliminated using active carbon chromatography with a stepwise gradient of water and 10.0% (v/v) ethanol. The purified solution was concentrated in an evaporator and freezedried. The MOS mixture (mannose; 1.0%, mannobiose; 35.4%, mannotriose; 25.9%, mannotetraose; 18.6%, mannopentaose; 10.0%, more than mannohexaose; 5.2% and moisture 3.9%) was used for human clinical tests.
Intake schedule Healthy volunteers consisting of two men and six women (from 18 to 45 years old, average 36.1 years) were assigned as subjects to test the effects of MOS on fecal analysis and defecation frequency. The MOS intake schedule is shown in Fig. 1 . After a 2 week observation period, each volunteer was administered 3.0 g of MOS per day for 2 weeks. After a 2 week no-dose interval period, each subject was then administered 1.0 g of MOS per day for 2 weeks. The volunteers dissolved the MOS in an appropriate volume of drinking water or a beverage such as green tea and drank it every day during the intake period. The intake time was not mandated. Throughout the entire examination period, the subjects had their meals in the ordinary way and recorded details of the meals. However, they were restricted from consuming foods and medicine that influenced intestinal microflora, such as fermented milk, indigestible oligosaccharide products, natto (fermented soybeans), antibiotic medicine and purgative medicine. The subjects collected whole parts of freshly voided feces in vinyl pouches at the end of each period. Fecal samples in the pouches were packed in aluminumcoated plastic bags with an Anaero-Pack (Mitsubishi Gas Chemical Co., Inc., Tokyo) and sent to the authors for keeping in cold E-mail: Ichiro Asano@agf.co.jp storage until analysis. This analysis of fecal microflora and pH was performed within 12 h after excretion. Specimens for SCFA analysis were kept at Ϫ20˚C and thawed just before analysis. This study, which was in accordance with the guidelines of the Helsinki Declaration, was approved by the Ethical Review Board of Ajinomoto General Foods, Inc.
Determination of fecal microflora Determination of the fecal microflora was carried out using the modified Mitsuoka method (Mitsuoka, 1982) . After the collected feces were made uniform by mashing them, 5 g of each fecal sample was dissolved in 45 ml of a diluent solution. One milliliter of 10-fold fecal solution was mixed with 9 ml of the diluent and then a series of 10-fold dilutions was prepared from 10 2 to 10 9 . A 0.05 ml sample of each dilution was inoculated on media. Three kinds of de-selective media (EG agar, BL agar and TS Blood agar) and ten kinds of selective media (BS agar, ES agar, Bacteroides agar, CW agar, Clostridia Count agar, Modified LBS agar, DHL agar, TATAC agar, PEES agar and P agar) were used for bacterial analyses ( Table 1) .
Determination of moisture, pH and SCFA in feces The moisture content was determined by drying 4 g of feces under reduced pressure in a vacuum oven at 70˚C. Fecal pH was directly measured by inserting a glass electrode into the feces. For SCFA analysis, 0.5 g of feces was mixed with 4.5 ml of 0.05 N H 2 SO 4 and homogenized. The 10-fold fecal solutions were centrifuged at 10,000 rpm for 10 min. The supernatant was used for HPLC analysis after being filtered through a 0.45 m membrane filter (Advantec, Tokyo). HPLC was performed with a Shimadzu LC-10 device and a refractive index detector (Erma EC-7512, Erma, Tokyo). A Merck-packed PolyspherOA KC column was used for anion exchange chromatography with 0.012 N H 2 SO 4 elution. The flow rate was maintained at 0.4 ml/min, and the sensitivity of detection was 1 g/ml.
Defecation frequency and visual fecal characteristics The volunteers observed their defecation (frequency and volume) and visual fecal characteristics and completed a questionnaire every day throughout the examination period. Fecal volume was determined as the approximate number of ping-pong balls equal to the volume of the feces (Inaki et al., 1999) . Visual fecal characteristics (color and shape) and smell were determined and scored by comparing the shape (Okada, 1985) and color against standard color sheets (Inaki et al., 1999) . Shape was scored between one (Firm) and six (Soft & watery) . Color was scored between one (Yellow) and six (Dark brown). Odor was scored between one (Weak) and five (Very strong). We delivered a ping-pong ball and a standard score sheet that showed fecal color and shape to the subjects. The subjects determined and scored their fecal volume, color and shape by comparison with the standard sheet; in addition, they were trained to determine their fecal volume and visual fecal characteristics for one week before the examination.
Statistical analysis
The results of the feces analysis were presented as mean values with standard errors. The data were analyzed using Bartlett test and this was followed by Fisher's Protected Least Significant Difference test. For the analysis of the defecation questionnaire, the data of the last week in each period, when the intestinal microflora had changed, were collected. The results of the defecation conditions were calculated as the mean values and standard errors of the last week. The data Bacterial counts were expressed as meanϮS.E. of log 10 per gram of wet feces (nϭ8). b) Frequency of occurrence was expressed as no. of subjects yielding the organism/no. of subjects examined. c) Lecithinase positve. * Statistically significant from the before intake (pϽ0.05). The all cultures were incubated at 37˚C for 48 h.
were analyzed for multiple differences using the Kruskal-Wallis test and this was followed by the Wilcoxon matched paired test. Statistical significance was accepted at a probability level of pϽ0.05.
Results

Influence of fecal microflora
The changes in fecal microflora caused by the administration of MOS are shown in Table 2 . Total bacteria, Eubacterium and Clostridium in feces were decreased, while Streptococcus was increased by a MOS intake of 3.0 g/day for 2 weeks (pϽ0.05). The frequency of Cl. perfringens in feces was decreased from 7/8 to 4/8 and the frequency of Lactobacillus was increased from 4/8 to 7/8 by the administration of 3.0 g of MOS for 2 weeks. No significant difference was observed in concentration of each bacterium in the feces before the intake period or during the interval period. Total bacteria counts, Eubacterium and Clostridium in feces were increased up to the original state by stopping the MOS 3.0 g/day intake, and the fecal microflora was changed again by reinstatement of the MOS administration. However, the fecal microflora in MOS 1.0 g/day differed from that of MOS 3.0 g/day. Bifidobacterium and Eubacterium in feces were significantly increased. The influence of MOS administration on the content of Bifidobacterium is depicted in Fig. 2 ; it significantly increased in both the MOS 3.0 g/day and 1.0 g/day administration periods (pϽ0.05). No significant difference was observed between the MOS 3.0 g/day and MOS 1.0 g/day trials.
Influences of moisture, pH and SCFA in feces Changes in moisture, pH and SCFA in feces are shown in Table 3 . Fecal moisture showed a slight tendency to increase during the MOS administration periods, while no significant differences among the four periods were noted in fecal pH and SCFA.
Influence of defecating conditions No abnormal symptoms related to physical condition of the eight volunteers was observed during any of the examination periods for MOS intake. Table 4 shows the results of the defecating conditions. The data presented represents the mean value per week for each subject. The defecation days and defecation frequency during the MOS 3.0 g/day intake period were significantly higher than before this period (pϽ0.05). The defecation days during the MOS 1.0 g/day intake period also rose significantly compared with that before the intake (pϽ0.05). However, no significant difference in defecation frequency between before the intake period and the MOS 1.0 g/day intake period was noted, nor were any significant changes in fecal volume or visual fecal characteristics observed.
Discussion
Extensive studies using clinical experiments have shown that various indigestible oligosaccharides affected fecal microflora and defecation conditions (Hidaka et al., 1986; Benno et al., 1987; Ito et al., 1990; Wada et al., 1991) . However, clinical experiments using MOS had never been reported. Tokunaga et al. (1993) administered three doses of fructooligosaccharides (FOS), 1.0 g/day, 3.0 g/day and 5.0 g/day, to healthy volunteers and investigated fecal microflora and defecation. In the present study, the effects of MOS intake on fecal microflora and defecation in healthy volunteers were investigated by administering 2 doses, 3.0 g/day and 1.0 g/day. As the minimum effective dose of MOS is not known, the authors began with administration of a high dose (3.0 g/day) thinking this probably more effective. After confirming the effectiveness of the MOS administration, a smaller dose was administered. After a 2 week interval, fecal microflora had returned to the same state as before any intake. Fecal microflora and defecation were compared before and after the MOS intake in an open test.
In this research, we first confirmed that the MOS 3.0 g/day intake caused a significant increase in the content of Bifidobacterium in feces (from 9.1% to 35.1%, pϽ0.05). This significant increase was due to a significant decrease of total bacteria and no change in Bifidobacterium by the MOS intake of 3.0 g/day. The frequency of Lactobacillus increased from 4/8 to 7/8. On the other hand, the frequency of Cl. perfringens that are typically harmful bacteria decreased from 7/8 to 4/8. This result seemed to suggest that the MOS intake changed the intestinal environment in which putrefactive bacteria do not proliferate. The population of Bifidobacterium during the MOS 3.0 g/day intake showed some variation, so that the mean seemed not to be increased by the intake. In the clinical test using FOS by Mitsuoka et al. (1987) , the populations of Bifidobacterium in feces were widely varied before the FOS intake depending on the subject, however, FOS intake caused the scatter to become much smaller. FOS are utilized by many kinds of Bifidobacterium spp. such as B. adolescentis, B. breve, B. infantis and B. longum . Therefore, Bifidobacterium spp. seems to be increased by the FOS intake without individual variation. On the other hand, MOS are used by a limited number of Bifidobacterium spp., B. adolescentis (Asano et al., 2001) , so that there might be few Bifidobacterium spp. that can utilize MOS in the intestine before the first MOS intake. It appears that the wide variation of Bifidobacterium in feces was caused by the difference of individual intestinal microflora, namely the difference in Bifidobacterium constituents. After the 2 week interval period, fecal microflora had statistically returned to their original state. The content of Bifidobacterium was significantly decreased due to increase of total bacteria but there was no change by interruption of the MOS intake. The increment of total bacteria seemed to be caused by proliferation of bacteria that do not utilize MOS. However, the frequency of Lactobacillus and Cl. perfringens did not completely return to the initial, pre-intake state. The first high dose intake may have influenced the frequency of those bacteria. The administration of MOS 1.0 g/day for 2 weeks statistically increased the content of Bifidobacterium from 17.1% to 30.5% (pϽ0.05) and the overall population of Bifidobacterium (pϽ0.05). It appears that a dose of MOS of 1.0 g/day also effectively increases the proliferation of Bifidobacterium. Moreover, Bifidobacterium content tended to increase with the MOS dose level. Bifidobacterium variation became much smaller during the MOS 1.0 g/day intake. This might suggest that the constituents of Bifidobacterium spp. changed during the first MOS intake, namely the percentage of the spp. that can utilize MOS increased, and the constituents were retained during the interval period. Bifidobacterium might significantly increase at even a small dose level when MOS intake is resumed.
Indigestible oligosaccharides escape digestion and encourage the proliferation of beneficial bacteria like Bifidobacterium in the intestine. These bacteria produce lactic acid or SCFA to lower the pH in the intestine and thereby inhibit the growth of harmful bacteria like Cl. perfringens (Hidaka et al., 1986) . A decrease in the frequency of Cl. perfringens suggests that the intestinal pH was lowered by the MOS administration. However, compared with prior to the intake significant increases of pH and SCFA in the feces were not observed in either MOS intake period. An intake of 1.0 g, 3.0 g, or 5.0 g/day of fructooligosaccharides significantly increased Bifidobacterium in the intestine but the pH of the feces did not fall (Tokunaga et al., 1993) , while an intake of 8.0 g/day lowered fecal pH . Tamai et al. (1992) reported that the fecal pH did not change with a 2.0 g/day intake of galactooligosaccharides, although an 8.0 g/day intake lowered the pH. They suggested that for a small dose of galactooligosaccharides insufficient amounts of organic acids were produced and thus the fecal pH was unaffected. On the other hand, Engelhardt (1995) reported that over 95% of SCFA produced in the large intestine were absorbed into the large intestinal epithelium cells. This suggested that the SCFA produced by the administration of small doses were absorbed in the large intestine. Therefore, it was theorized from this study that lack of a significant drop in the pH is due to the fact that most of the SCFA does not remain in feces to lower pH, even though intestinal pH is lowered by the SCFA produced from the MOS.
The volunteers recorded their daily defecation throughout the test period. The defecating days and times of defecation weekly were significantly increased under the administration of the high dose, compared to before the MOS intake (pϽ0.05). The weekly defecation frequency for the administration of 1.0 g/day of MOS was greater than before the intake (pϽ0.05). Dose dependence on defecation times was identified. However, MOS ingestion did not affect fecal volume or fecal characteristics in one week. The volunteers assigned to this study defecated 4.5 days/week before the MOS intake. This suggested that they did not suffer from obstinate constipation and were healthy at least in regard to defecation. Their scores for feces volume, visual and smell characteristics were in the normal range before MOS ingestion. Therefore, it seems that MOS administration did not cause marked improvement in feces volume or characteristics. Furthermore, this examination was not carried out with a completely controlled menu, and the fecal volume was not observed by actual weight measurement. The lack of effect of MOS intake on fecal volume might be due to these experimental conditions and method. In order to confirm the exact effects on fecal volume or characteristics by MOS intake, a clinical experiment under which the complete menu and the subjects are controlled is required, and actual feces weight should be measured.
In conclusion, Bifidobacterium became the predominant bacteria in feces with the ingestion of MOS 1.0 g/day and 3.0 g/day. Defecating conditions were improved for both dosages. These results suggest that the MOS escaped digestion and was selectively utilized by Bifidobacterium in the large intestine. Under the continual intake of MOS it is expected that Bifidobacterium will become the dominant strain in the large intestine and defecation will be improved. Moreover, depending on the dosage level MOS intake had a tendency to improve the content of Bifidobac-terium and thus the defecating conditions. Small dose administration studies are required to identify the minimum effective dose of MOS on Bifidobacterium increments in the large intestine.
